DNL-151 and DNL-201 are both small-molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) are being developed for treating Parkinson's disease. Some mutations in the LRRK2 gene increase the activity of this enzyme and have been linked to a high risk of Parkinson’s, due to a LRRK2-increased risk of neuron death.

DNL-747 is a small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) that is being developed for treating Alzheimer’s disease and ALS.

BearDownAZ